Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Buy” by Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA) has earned a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $32.29.

A number of research analysts have recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Vera Therapeutics in a research report on Monday, January 8th. They set an “overweight” rating for the company. Wedbush increased their price objective on Vera Therapeutics from $21.00 to $34.00 and gave the company a “neutral” rating in a report on Thursday, March 21st. Guggenheim reissued a “buy” rating and issued a $56.00 target price on shares of Vera Therapeutics in a research report on Friday, April 5th. Oppenheimer began coverage on Vera Therapeutics in a research report on Thursday, January 25th. They set an “outperform” rating and a $26.00 price target on the stock. Finally, Raymond James raised Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $29.00 to $37.00 in a report on Friday, January 26th.

Insiders Place Their Bets

In related news, Director Maha Katabi purchased 161,290 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were purchased at an average cost of $31.00 per share, for a total transaction of $4,999,990.00. Following the completion of the transaction, the director now directly owns 3,628,446 shares in the company, valued at approximately $112,481,826. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Maha Katabi purchased 161,290 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was purchased at an average cost of $31.00 per share, with a total value of $4,999,990.00. Following the acquisition, the director now directly owns 3,628,446 shares in the company, valued at $112,481,826. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Sean Grant sold 99,828 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $39.61, for a total transaction of $3,954,187.08. Following the completion of the transaction, the chief financial officer now directly owns 66,337 shares in the company, valued at approximately $2,627,608.57. The disclosure for this sale can be found here. Insiders sold a total of 526,551 shares of company stock worth $21,533,345 in the last quarter. 21.70% of the stock is owned by company insiders.

Institutional Trading of Vera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of VERA. Amalgamated Bank increased its position in shares of Vera Therapeutics by 26.0% in the third quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock worth $57,000 after purchasing an additional 864 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Vera Therapeutics in the 4th quarter worth approximately $79,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Vera Therapeutics in the 3rd quarter worth $79,000. SG Americas Securities LLC purchased a new stake in shares of Vera Therapeutics during the 4th quarter valued at $119,000. Finally, Pale Fire Capital SE purchased a new stake in shares of Vera Therapeutics during the 4th quarter valued at $252,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $38.69 on Friday. The firm has a market capitalization of $2.11 billion, a P/E ratio of -16.90 and a beta of 1.05. The company has a current ratio of 7.71, a quick ratio of 7.71 and a debt-to-equity ratio of 0.49. The business’s fifty day simple moving average is $43.24 and its 200 day simple moving average is $26.66. Vera Therapeutics has a 12 month low of $6.07 and a 12 month high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.05). As a group, analysts anticipate that Vera Therapeutics will post -2.18 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.